41.93 -0.03 (-0.06%)
After hours: 4:09PM EDT
|Bid||0.00 x 3200|
|Ask||43.00 x 3000|
|Day's Range||41.58 - 42.06|
|52 Week Range||37.43 - 50.65|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||1.86 (4.38%)|
|1y Target Est||44.00|
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 11) AC Immune SA (NASDAQ: ACIU ) Arbutus Biopharma Corp (NASDAQ: ...
Myokardia Inc (NASDAQ: MYOK ) stock is up 290 percent year-over-year, but upcoming stimulants could drive additional outperformance, according to Bank of America Merrill Lynch. The Analyst BofA's Tazeen ...
LAVAL, QC , July 10, 2018 /CNW Telbec/ - Sanofi Genzyme is disappointed with the recent recommendation by the Canadian Agency for Drugs and Technologies in Health (CADTH) to not reimburse Dupixent™, one of the most important recent pharmacological innovations for the treatment of adult patients with moderate-to-severe atopic dermatitis (AD). This recommendation disregards patient input and ignores the product's clinical value and the potential improvement to patient and caregiver quality-of-life (QoL). In 2017, Health Canada, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved Dupixent™ based on its clinical value and benefits to patients with moderate-to-severe AD.
The French government said on Tuesday that it was monitoring the situation at Sanofi's Mourenx plant in southwestern France to ensure the drugmaker had taken steps against pollution problems before it would allow the plant to re-open. Sanofi said on Monday that it had stopped production at the plant after an environment body filed a complaint against what it said was massive air pollution. France Nature Environnement, a federation representing some 3,500 local associations, said emissions at the Mourenx plant, which produces the epilepsy treatment valproate, had been 7,000 times above the limit allowed by French law.
Regulus Therapeutics (RGLS) announces strategic and restructuring plans to extend cash runway. However, investors remain skeptical.
On July 3, the Financial Times reported that Pfizer Inc. (NYSE:PFE) is increasing the prices of 100 of its drugs by around 10 percent. Value investors looking to buy in should stick with drug stocks trading at favorable valuations and whose business faces multiple positive catalysts ahead. Here are 5 biotech stocks to get you started for July.
On Thursday, July 05, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. All sectors ended Thursday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Drug Manufacturers - Major equities this morning: Heron Therapeutics Inc. (NASDAQ: HRTX), Immune Pharmaceuticals Inc. (NASDAQ: IMNP), Johnson & Johnson (NYSE: JNJ), and Sanofi (NYSE: SNY).
The US pharmaceutical sector comprises drug manufacturers, drug marketers, and biotechnology companies. The chart below lists some recent mergers and acquisitions in the sector.
On January 29, Sanofi announced its acquisition of Ablynx for $4.8 billion, and it announced the completion of the acquisition on June 19. The acquisition was one of two announced in January to advance its blood disorder portfolio. The other acquisition was of Bioverative.
On June 25, Sanofi and Evotec reached the second milestone of the diabetes business alliance they entered into in August 2015, with a payment of 3 million euros from Sanofi to Evotec after the latter had met “pre-agreed critical success criteria for a potential manufacturing process” for generating human induced pluripotent stem cell-derived beta cells. The deal aims to extend Evotec’s metabolic disease and stem cell-based drug discovery programs and enhance Sanofi’s extensive diabetes research and development pipeline. According to the agreement, Evotec is eligible to receive as much as 300 million euros in milestone-based payments from Sanofi as well as royalties and research payments. To date, the company has received 9 million euros in upfront milestone-based payments and research funding from Sanofi.
On June 15, Sanofi (SNY) and Evotec, a Germany-based drug discovery and development company, signed an agreement to transfer Sanofi’s anti-infectives unit to Evotec for $70 million. Sanofi will also transfer 100 employees to Evotec and licenses for more than ten infectious disease R&D (research and development) pipeline assets.
On June 25, Sanofi (SNY) announced positive results for BRIGHT, a study comparing Sanofi’s Toujeo with Novo Nordisk’s (NVO) Tresiba (degludec). The study results were presented at the American Diabetes Association’s 78th Scientific Sessions in Orlando, Florida.
Sanofi (SASY.PA) sees a more diversified pipeline driving a return to growth at its diabetes unit in the coming years and will consider acquisitions and partnerships to help boost performance, a company executive said on Tuesday. The French drugmaker's diabetes revenues have fallen since 2015, slumping some 11 percent last year alone, as its patent-expired Lantus insulin is being squeezed by pricing pressure in the United States, the world's-largest health market. "I will not commit to a new guidance for 2019 but we are clearly optimistic for the business," Stefan Oelrich, executive vice president for diabetes and cardiovascular at Sanofi, told Reuters.
Sanofi sees a more diversified pipeline driving a return to growth at its diabetes unit in the coming years and will consider acquisitions and partnerships to help boost performance, a company executive said on Tuesday. The French drugmaker's diabetes revenues have fallen since 2015, slumping some 11 percent last year alone, as its patent-expired Lantus insulin is being squeezed by pricing pressure in the United States, the world's-largest health market. "I will not commit to a new guidance for 2019 but we are clearly optimistic for the business," Stefan Oelrich, executive vice president for diabetes and cardiovascular at Sanofi, told Reuters.
On June 26, Sensile Medical, a Swiss company developing liquid drug-delivery devices, announced that it had entered into a partnership with Sanofi and Verily (formerly Google Life Sciences) for the development and commercialization of a connected insulin patch pump. The below diagram shows Sanofi’s research and development pipeline. In their alliance, the three companies aim to leverage Sensile Medical’s micro-pump technology development leadership, Sanofi’s expertise in insulin and diabetes solutions, and Verily’s experience in micro-electronic integration and digital healthcare technology.
SNY stock is trading higher than its 50-day moving average of $38.84 and marginally lower than its 200-day moving average of $40.77. Over the last year, Sanofi stock had fallen ~19% as of June 26, while the healthcare industry (XLV) had risen ~5.3%. Peers GlaxoSmithKline (GSK), Pfizer (PFE), and Eli Lilly (LLY) had returned -8.8%, 7.7%, and 2.5%, respectively. In the next article, we’ll discuss Sanofi’s recent partnership with Sensile Medical and Verily in the insulin pump business.
Sanofi (SNY) has recently been working on expanding its product portfolio in areas with potential growth and strong margins. As the Sanofi posted weak Q1 2018 performance, mainly triggered by weakness in its diabetes and cardiovascular business, the company has recently entered into a number of collaborations and initiatives to recuperate its business. Let’s look at Sanofi’s valuation metrics as of June 27.
Sanofi, a global healthcare leader, has a comprehensive product portfolio and pipeline focusing on immunology, oncology, multiple sclerosis, neurology, rare disease disorders, diabetes, cardiovascular diseases, vaccines, and infectious diseases. In Q1 2018, the company’s sales fell and its missed analysts’ estimates. Let’s begin by looking at analysts’ recommendations for SNY stock for the next 12 months.
Regeneron Pharmaceuticals and Sanofi made a first-ever price increase for Dupixent, a potential blockbuster eczema treatment, an analyst said Monday.
- Company invests €66 million in Chengdu, Sichuan province, China - China is the third pillar of Sanofi Global Clinical Sciences and Operations, developing digitalization and big data analysis CHENGDU, ...
As for each quarter, Sanofi prepared this document to assist in the financial modeling of the Group`s quarterly results. Sanofi`s second-quarter results will be published on July 31, 2018. Sanofi is dedicated to supporting people through their health challenges.
June 29, 2018 - The European Medicines Agency`s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Cablivi (caplacizumab) in Europe for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood-clotting disorder. Cablivi was developed by Ablynx, a Sanofi Company. The European Commission will review the CHMP recommendation and a final decision on the Marketing Authorisation Application for Cablivi in the European Union is expected in the coming months.